KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Cash & Current Investments (2016 - 2025)

Amgen has reported Cash & Current Investments over the past 17 years, most recently at $9.1 billion for Q4 2025.

  • Quarterly results put Cash & Current Investments at $9.1 billion for Q4 2025, down 23.75% from a year ago — trailing twelve months through Dec 2025 was $9.1 billion (down 23.75% YoY), and the annual figure for FY2025 was $9.1 billion, down 23.75%.
  • Cash & Current Investments for Q4 2025 was $9.1 billion at Amgen, down from $9.4 billion in the prior quarter.
  • Over the last five years, Cash & Current Investments for AMGN hit a ceiling of $34.7 billion in Q3 2023 and a floor of $6.5 billion in Q1 2022.
  • Median Cash & Current Investments over the past 5 years was $9.4 billion (2022), compared with a mean of $13.0 billion.
  • Biggest five-year swings in Cash & Current Investments: soared 382.29% in 2023 and later crashed 74.03% in 2024.
  • Amgen's Cash & Current Investments stood at $8.0 billion in 2021, then grew by 15.78% to $9.3 billion in 2022, then increased by 17.61% to $10.9 billion in 2023, then grew by 9.4% to $12.0 billion in 2024, then decreased by 23.75% to $9.1 billion in 2025.
  • The last three reported values for Cash & Current Investments were $9.1 billion (Q4 2025), $9.4 billion (Q3 2025), and $8.0 billion (Q2 2025) per Business Quant data.